Pharma Journalist -

GlaxoSmithKline plc announced that patient dosing has begun in a phase III clinical programme investigating gepotidacin, the first in a new chemical class of antibiotics called…
Read More...

Ziopharm Oncology and The University of Texas MD Anderson Cancer Center announced a new research and development agreement relating to Ziopharm’s Sleeping Beauty immunotherapy program…
Read More...

CARsgen Therapeutics Co. Ltd., a clinical-stage biopharmaceutical company announced that the United States Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced…
Read More...

Gilead Sciences Inc. and Glympse Bio, Inc., announced that the companies have entered into a strategic collaboration in nonalcoholic steatohepatitis (NASH) clinical development. Glympse…
Read More...

SMi Reports: Registration is open for SMi’s inaugural AI in Drug Discovery conference taking place in London in March 2020. SMi is delighted to announce the highly anticipated AI in…
Read More...

SMi has released an exclusive interview with industry expert Richard Marsden, CEO of Synairgen, ahead of the upcoming Respiratory Drug Delivery conference this December. Respiratory…
Read More...

HistoIndex announces the expansion of its AI-based digital pathology platform towards large-scale NASH preclinical programs for pharmaceutical and biotech companies to achieve…
Read More...

Shifting the paradigm from targeting protein to targeting RNA requires rethinking several aspects of drug discovery including target selection, lead discovery, assays to support lead…
Read More...

Panel Discussion: Targeting RNA with Small Molecules to Capture the Therapeutic Opportunities At this year’s 2nd RNA-Targeted Drug Discovery Summit (December 2-4, Boston), an expert…
Read More...

The recent expansion of the RNA space has resulted in the emergence of many specialised biotechs, particularly in North America and Europe. Investment ranges from $30-70mil across the…
Read More...